$2.14
3.63% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US2936021086
Symbol
ENSC
Sector
Industry

Ensysce Biosciences Inc Stock price

$2.14
-0.05 2.28% 1M
-3.98 65.03% 6M
-6.00 73.71% YTD
-5.90 73.38% 1Y
-37,652.42 99.99% 5Y
-34,737.86 99.99% 10Y
-34,737.86 99.99% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
+0.08 3.63%
ISIN
US2936021086
Symbol
ENSC
Sector
Industry

Key metrics

Market capitalization $5.07m
Enterprise Value $2.27m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 0.37
P/S ratio (TTM) P/S ratio 0.82
P/B ratio (TTM) P/B ratio 1.15
Revenue growth (TTM) Revenue growth 255.43%
Revenue (TTM) Revenue $6.22m
EBIT (operating result TTM) EBIT $-6.85m
Free Cash Flow (TTM) Free Cash Flow $-5.80m
Cash position $3.05m
EPS (TTM) EPS $-4.86
P/S forward 7.68
EV/Sales forward 3.44
Short interest 4.18%
Show more

Is Ensysce Biosciences Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Ensysce Biosciences Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

1 Analyst has issued a forecast Ensysce Biosciences Inc:

1x Buy
100%

Analyst Opinions

1 Analyst has issued a forecast Ensysce Biosciences Inc:

Buy
100%

Financial data from Ensysce Biosciences Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
6.22 6.22
255% 255%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 4.75 4.75
8% 8%
76%
- Research and Development Expense 8.33 8.33
27% 27%
134%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -6.85 -6.85
31% 31%
-110%
Net Profit -6.82 -6.82
41% 41%
-110%

In millions USD.

Don't miss a Thing! We will send you all news about Ensysce Biosciences Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ensysce Biosciences Inc Stock News

Neutral
Accesswire
2 days ago
~ Pain Management, RE-Invented: A New Era for Analgesia ~ SAN DIEGO, CA / ACCESS Newswire / June 11, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for abuse and overdose, today announced a world-class panel to discuss the current state of pai...
Neutral
Accesswire
9 days ago
~ PF614-MPAR Moving to Next Stage of Development, Finalizing Drug Formulation ~ ~ Funds Accelerate Path Towards Commercialization ~ SAN DIEGO, CA / ACCESS Newswire / June 4, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential for opioid abuse and o...
Neutral
Accesswire
about one month ago
Receives U.S. Patent for Groundbreaking Treatment for Opioid Use Disorder Clinical Trial on Novel Analgesic, PF614-MPAR, Demonstrates Overdose Protection SAN DIEGO, CA / ACCESS Newswire / May 13, 2025 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative solutions for severe pain relief while reducing the potential ...
More Ensysce Biosciences Inc News

Company Profile

Ensysce Biosciences, Inc. is a clinical-stage biopharmaceutical company. It is focused on proprietary technology platforms to develop safer prescription drugs. The firm's Trypsin Activated Abuse Protection and Multi-Pill Abuse Resistance platforms, are in the process of developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. The company is headquartered in La Jolla, CA.

Head office United States
CEO D. Kirkpatrick
Employees 8
Founded 2003
Website ensysce.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today